Brivaracetam in Unverricht-Lundborg disease (EPM1): Results from two randomized, double-blind, placebo-controlled studies

A randomized, double-blind, placebo-controlled, multicenter, parallel-group study to evaluate the efficacy and safety of adjunctive brivaracetam in adult patients with uncontrolled partial-onset seizures

(2015) Pavel Klein et al.   EPILEPSIA

Refining the phenotype of Unverricht-Lundborg disease (EPM1): A population-wide Finnish study

(2015) J. Hypponen et al.   NEUROLOGY

Brivaracetam as adjunctive treatment for uncontrolled partial epilepsy in adults: A phase III randomized, double-blind, placebo-controlled trial

(2013) Victor Biton et al.   EPILEPSIA

Adjunctive brivaracetam for uncontrolled focal and generalized epilepsies: Results of a phase III, double-blind, randomized, placebo-controlled, flexible-dose trial

(2013) Patrick Kwan et al.   EPILEPSIA

Adjunctive brivaracetam in adults with uncontrolled focal epilepsy: Results from a double-blind, randomized, placebo-controlled trial

(2013) Philippe Ryvlin et al.   EPILEPSIA

Efficacy and tolerability of adjunctive brivaracetam in adults with uncontrolled partial-onset seizures: A phase IIb, randomized, controlled trial

(2012) Wim Van Paesschen et al.   EPILEPSIA

Binding characteristics of brivaracetam, a selective, high affinity SV2A ligand in rat, mouse and human brain: Relationship to anti-convulsant properties

(2011) Michel Gillard et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

A pilot open-label trial of zonisamide in Unverricht-Lundborg disease

(2010) Domenico Italiano et al.   MOVEMENT DISORDERS

Adjunctive brivaracetam for refractory partial-onset seizures: A randomized, controlled trial

(2010) J. A. French et al.   NEUROLOGY

Anti-convulsive and anti-epileptic properties of brivaracetam (ucb 34714), a high-affinity ligand for the synaptic vesicle protein, SV2A

(2008) A Matagne et al.   BRITISH JOURNAL OF PHARMACOLOGY

Clinical picture of EPM1-Unverricht-Lundborg disease

(2008) Reetta Kälviäinen et al.   EPILEPSIA